Published in Clin Cancer Res on June 09, 2009
High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis (2010) 1.87
MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer (2010) 1.74
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array. PLoS One (2011) 1.49
MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2. PLoS One (2015) 1.48
Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res (2010) 1.44
The role of microRNAs in colorectal cancer. Cancer J (2012) 1.44
Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One (2011) 1.39
PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis. Virchows Arch (2011) 1.28
Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol (2011) 1.19
The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA (2012) 1.18
MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer (2011) 1.17
MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene (2015) 1.16
Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol (2010) 1.13
The prognostic importance of miR-21 in stage II colon cancer: a population-based study. Br J Cancer (2012) 1.12
Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma. PLoS One (2013) 1.11
MicroRNA-21 as a potential colon and rectal cancer biomarker. World J Gastroenterol (2013) 1.10
MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol Sin (2011) 1.08
MicroRNA dysregulation as a prognostic biomarker in colorectal cancer. Cancer Manag Res (2014) 1.05
Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. Clin Cancer Res (2015) 1.03
Exosome can prevent RNase from degrading microRNA in feces. J Gastrointest Oncol (2011) 1.01
Endocrine disruptor regulation of microRNA expression in breast carcinoma cells. PLoS One (2012) 1.00
Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn (2011) 0.97
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget (2016) 0.94
PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis. Virchows Arch (2012) 0.93
MiR-21 expression in the tumor stroma of oral squamous cell carcinoma: an independent biomarker of disease free survival. PLoS One (2014) 0.93
Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Lab Invest (2014) 0.92
miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas. Oncotarget (2015) 0.90
Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Invest (2011) 0.89
Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. J Clin Pathol (2010) 0.88
Cathepsin E is a marker of gastric differentiation and signet-ring cell carcinoma of stomach: a novel suggestion on gastric tumorigenesis. PLoS One (2013) 0.88
MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis (2015) 0.88
Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine? Expert Rev Mol Diagn (2014) 0.87
Combined fluorescent in situ hybridization for detection of microRNAs and immunofluorescent labeling for cell-type markers. Front Cell Neurosci (2013) 0.87
An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn (2014) 0.87
Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. Oncol Lett (2011) 0.84
Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort. Br J Cancer (2014) 0.83
Quantitatively controlling expression of miR-17~92 determines colon tumor progression in a mouse tumor model. Am J Pathol (2014) 0.83
miRNAs as biomarkers for management of patients with colorectal cancer. Biomark Med (2010) 0.83
MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer. World J Gastrointest Oncol (2016) 0.82
Alterations of MicroRNAs in Solid Cancers and Their Prognostic Value. Cancers (Basel) (2010) 0.82
Combined assays for serum carcinoembryonic antigen and microRNA-17-3p offer improved diagnostic potential for stage I/II colon cancer. Mol Clin Oncol (2015) 0.81
Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy. Curr Genomics (2015) 0.81
microRNA-17 Is the Most Up-Regulated Member of the miR-17-92 Cluster during Early Colon Cancer Evolution. PLoS One (2015) 0.81
The involvement of miR-23a/APAF1 regulation axis in colorectal cancer. Int J Mol Sci (2014) 0.81
The miR-199a/Brm/EGR1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines. Sci Rep (2015) 0.81
Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. BMC Med Genomics (2014) 0.79
A microRNA component of the neoplastic microenvironment: microregulators with far-reaching impact. Biomed Res Int (2012) 0.79
Regulatory Roles of Non-Coding RNAs in Colorectal Cancer. Int J Mol Sci (2015) 0.79
PDCD4 expression in thyroid neoplasia. Virchows Arch (2012) 0.78
MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells. PLoS One (2016) 0.78
Small RNA Detection by in Situ Hybridization Methods. Int J Mol Sci (2015) 0.77
The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation. J Biomed Sci (2016) 0.77
Stromal Expression of MicroRNA-21 in Advanced Colorectal Cancer Patients with Distant Metastases. J Pathol Transl Med (2016) 0.76
Fluorescence In Vivo Hybridization (FIVH) for Detection of Helicobacter pylori Infection in a C57BL/6 Mouse Model. PLoS One (2016) 0.75
Genetic alterations and epigenetic alterations of cancer-associated fibroblasts. Oncol Lett (2016) 0.75
Investigation of MicroRNA-21 Expression Levels in Serum and Stool as a Potential Non-Invasive Biomarker for Diagnosis of Colorectal Cancer. Iran Biomed J (2016) 0.75
Demonstration of hepatitis C virus RNA with in situ hybridization employing a locked nucleic Acid probe in humanized liver of infected chimeric mice and in needle-biopsied human liver. Int J Hepatol (2013) 0.75
The hallmarks of premalignant conditions: a molecular basis for cancer prevention. Semin Oncol (2015) 0.75
miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients. Oncotarget (2017) 0.75
MicroRNA-142-5p contributes to Hashimoto's thyroiditis by targeting CLDN1. J Transl Med (2016) 0.75
MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications. Dis Model Mech (2017) 0.75
Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res (2004) 5.46
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol (2011) 3.88
Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer (2005) 3.69
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology (2005) 3.26
miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol (2008) 3.26
Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res (2005) 3.19
Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet (2011) 3.19
Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med (2005) 3.18
Outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms in 200 consecutive cases. Clin Gastroenterol Hepatol (2007) 3.13
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology (2011) 3.00
Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer (2004) 2.88
Risk assessment for delayed hemorrhagic complication of colonic polypectomy: polyp-related factors and patient-related factors. Gastrointest Endosc (2006) 2.78
Endoscopic submucosal dissection of esophageal squamous cell neoplasms. Clin Gastroenterol Hepatol (2006) 2.75
Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology (2008) 2.70
High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res (2006) 2.69
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology (2009) 2.59
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest (2011) 2.54
Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res (2009) 2.52
Northern Hemisphere forcing of climatic cycles in Antarctica over the past 360,000 years. Nature (2007) 2.47
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol (2013) 2.46
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int (2005) 2.46
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res (2003) 2.44
Single-balloon versus double-balloon endoscopy for achieving total enteroscopy: a randomized, controlled trial. Gastrointest Endosc (2011) 2.39
A randomized controlled trial evaluating the usefulness of a transparent hood attached to the tip of the colonoscope. Am J Gastroenterol (2006) 2.35
Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc (2013) 2.30
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Tissue damage of different submucosal injection solutions for EMR. Gastrointest Endosc (2005) 2.27
A second-look endoscopy after endoscopic submucosal dissection for gastric epithelial neoplasm may be unnecessary: a retrospective analysis of postendoscopic submucosal dissection bleeding. Gastrointest Endosc (2009) 2.24
Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int (2008) 2.15
Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin Gastroenterol Hepatol (2003) 2.13
Successful outcomes of a novel endoscopic treatment for GI tumors: endoscopic submucosal dissection with a mixture of high-molecular-weight hyaluronic acid, glycerin, and sugar. Gastrointest Endosc (2006) 2.13
Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer (2011) 2.09
Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology (2003) 2.06
HIV-1 nef suppression by virally encoded microRNA. Retrovirology (2004) 2.05
Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc (2009) 2.05
Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol (2006) 2.05
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Endoscopic evaluation of the remnant stomach after gastrectomy: proposal for a new classification. Gastric Cancer (2002) 2.01
Endoscopic submucosal dissection for gastrointestinal neoplasms. World J Gastroenterol (2008) 1.98
Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res (2008) 1.91
Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology (2006) 1.90
Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology (2008) 1.88
Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer (2006) 1.87
Endoscopic submucosal dissection using flexknife. J Clin Gastroenterol (2006) 1.83
Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol (2009) 1.80
Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res (2010) 1.80
Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology (2002) 1.79
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2006) 1.78
Report of the 15th follow-up survey of primary liver cancer. Hepatol Res (2004) 1.78
Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol (2008) 1.78
Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med (2003) 1.70
Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol (2011) 1.70
Detection of common bile duct stones: comparison between endoscopic ultrasonography, magnetic resonance cholangiography, and helical-computed-tomographic cholangiography. Eur J Radiol (2005) 1.68
DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer (2009) 1.66
Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res (2005) 1.65
UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection. Clin Cancer Res (2004) 1.62
Class-specific regulation of pro-inflammatory genes by MyD88 pathways and IkappaBzeta. J Biol Chem (2008) 1.62
Efficacy and safety of low-pressured and short-time dilation in endoscopic papillary balloon dilation for bile duct stone removal. J Gastroenterol Hepatol (2007) 1.60
Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol (2004) 1.56
Endoscopic papillary balloon dilation for the management of bile duct stones in patients 85 years of age and older. Gastrointest Endosc (2008) 1.56
Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology (2002) 1.55
Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. J Gastroenterol (2009) 1.55
Right-side shift of colorectal adenomas with aging. Gastrointest Endosc (2006) 1.55
Novel image-enhanced endoscopy with i-scan technology. World J Gastroenterol (2010) 1.53
Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis. Int J Cancer (2012) 1.53
Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res (2005) 1.51
Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology (2005) 1.50
Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci (2008) 1.49
Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol (2010) 1.49
Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res (2009) 1.49
Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med (2004) 1.48
Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer (2009) 1.47
Impact of introduction of wire-guided cannulation in therapeutic biliary endoscopic retrograde cholangiopancreatography. J Gastroenterol Hepatol (2011) 1.47
Assessment of the risk factors for colonic diverticular hemorrhage. Dis Colon Rectum (2007) 1.46
Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros. Dig Liver Dis (2010) 1.45
Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut (2007) 1.43
Endogenous prostaglandin D2 synthesis reduces an increase in plasminogen activator inhibitor-1 following interleukin stimulation in bovine endothelial cells. J Hypertens (2002) 1.43
HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene (2002) 1.43
Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly. J Gastroenterol (2010) 1.43
Early gastric cancer shows different associations with adipose tissue volume depending on histological type. Gastric Cancer (2008) 1.42
MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun (2011) 1.41
Endoscopic submucosal dissection for stomach neoplasms. World J Gastroenterol (2006) 1.41